Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lyra Therapeutics (LYRA) EBITDA Margin (2021 - 2025)

Lyra Therapeutics has reported EBITDA Margin over the past 5 years, most recently at 99300.0% for Q4 2025.

  • Quarterly results put EBITDA Margin at 99300.0% for Q4 2025, down 9403732.0% from a year ago — trailing twelve months through Dec 2025 was 7266.08% (down 117299.0% YoY), and the annual figure for FY2025 was 7266.08%, down 117299.0%.
  • EBITDA Margin for Q4 2025 was 99300.0% at Lyra Therapeutics, down from 23936.0% in the prior quarter.
  • Over the last five years, EBITDA Margin for LYRA hit a ceiling of 2545.09% in Q1 2022 and a floor of 129318.18% in Q4 2022.
  • Median EBITDA Margin over the past 5 years was 4847.61% (2021), compared with a mean of 22160.93%.
  • Biggest five-year swings in EBITDA Margin: plummeted -12429346bps in 2022 and later surged 11896476bps in 2023.
  • Lyra Therapeutics' EBITDA Margin stood at 5024.72% in 2021, then crashed by -2474bps to 129318.18% in 2022, then soared by 92bps to 10353.42% in 2023, then surged by 49bps to 5262.68% in 2024, then tumbled by -1787bps to 99300.0% in 2025.
  • The last three reported values for EBITDA Margin were 99300.0% (Q4 2025), 23936.0% (Q3 2025), and 4063.93% (Q2 2025) per Business Quant data.